




## Ongoing Clinical Trials




EARLY ACS-(TIMI 39) is a randomized, double-blind, placebo-controlled trial designed to assess whether upfront use of eptifibatide with a double-bolus is beneficial in patients with high-risk ACS planned for an early invasive strategy.




IMPROVE IT-(TIMI 39) is a randomized, double-blind trial designed to assess the benefit of treating to LDL goals even lower than those targeted in PROVE IT-TIMI 22 with a combination of simvastatin and ezetimibe in patients stabilized after ACS.




PLATO-(TIMI 41) is a randomized, double-blind trial to assess the efficacy of AZD6140, an oral, reversible P2Y12 inhibitor, compared with clopidogrel for prevention of vascular events in patients across the spectrum of ACS.




SEPIA-ACS 1 is a randomized, blinded, dose-ranging study to evaluate the clinical efficacy and safety of otamixaban, a direct Factor Xa inhibitor, in patients with moderate-to-high risk NSTEMI-ACS and a planned early invasive strategy.




AVANT GARDE-TIMI 43 is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of aliskiren, a renin antagonist, and valsartan, an angiotensin receptor blocker, in lowering levels of NT-proBNP in stabilized patients after ACS.




VERIFY NOW-TIMI 45 will assess the correlation of the percent platelet inhibition as measured by the VerifyNow<sup>®</sup> system with the risk of peri-operative bleeding in patients on clopidogrel undergoing coronary artery bypass grafting.




ATLAS ACS-TIMI 46 is a randomized, double-blind, placebo-controlled, dose-ranging trial to assess the safety and efficacy of rivaroxaban, a Factor Xa inhibitor, in combination with aspirin alone or aspirin and a thienopyridine in patients presenting across the spectrum of ACS.




IC-TITAN-TIMI 47 is a randomized, open-label, placebo-controlled trial to assess the efficacy and safety of intra-coronary eptifibatide versus placebo in patients undergoing PCI for STEMI.



ENGAGE-AF-TIMI 48 is a randomized, double-blind trial to assess the efficacy and safety of DU-176b, an oral Factor Xa inhibitor, versus warfarin in preventing thromboembolic events in patients with moderate-high risk atrial fibrillation.



ICE-T-TIMI 49 is a randomized, open-label, placebo-controlled trial to assess the efficacy and safety of low-dose intracoronary tenecteplase in patients undergoing primary PCI for STEMI.



TRA2P-TIMI 50 is a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of SCH 530348, a platelet thrombin receptor antagonist, in preventing clinical events in patients with stable atherosclerotic disease.